Pancreatic Adenocarcinoma Metastatic Withdrawn Phase 2 Trials for CPI-613 (DB12109)

Also known as: Metastatic Pancreatic Adenocarcinoma / Pancreatic carcinoma metastatic

IndicationStatusPhase
DBCOND0060224 (Pancreatic Adenocarcinoma Metastatic)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01830322Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic CancerTreatment